by Daniel X. Thomas
EP 2 962 690 B1 is a 2d generation divisional and relates to (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline1,3-dione, or a pharmaceutically acceptable polymorph, salt, solvate or hydrate thereof, and to the (+) enantiomer for use as a medicament.
Brief outline of the case
The patent was maintained according to AR3.
The proprietor and opponents 1-8 and 11-14,
by Daniel X. Thomas
EP 2 397 156 relates to “Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway”.
Claim 1 is drafted in the form of a purpose-limited product claim, pursuant to Art 54(5), and is directed to a compound that reduces the activity or expression of a Programmed Cell Death-1 (PD-1) polypeptide=”PD-1 inhibitor”,
by Daniel X. Thomas
EP 2 371 361 B1 relates to methods to mobilise progenitor/stem cells in subjects by administering certain polyamines.
Brief outline of the case
The patent was maintained by the OD according to AR6.
The proprietor and opponents 1, 2, 4, 5 and 6 (out of 7) each lodged an appeal against the OD’s decision.
by Daniel X. Thomas
EP 3 361 885 B1 relates to nutrition for infants, in particular infant formula, intended to be used as a sole source of nutrition. In other words, it replaces mother milk.
Brief outline of the case
The opposition was rejected and both opponents appealed.
The OD considered that the claims at stake where related to a medical use and were purpose limited claims under Art 54(5) used in a method of according to Art 53(c).
by Daniel X. Thomas
The patent relates to long-acting formulations of insulin and has already been discussed in the present blog but under a different topic.
Brief outline of the case
The opponent appealed the decision of maintenance according to a new MR filed during OP before the OD.
In the summons to OP before the OD,